Aims Little is known about the role of genetic variants in the early stages of age-related macular degeneration (AMD). We aimed to investigate how genetic variations within five well-defined genes relate to AMD severity. Methods We analysed SNPs in the genes for complement factor H (CFH), age-related maculopathy susceptibility (ARMS2), HtrA serine peptidase 1 (HtrA1), complement factor B (CFB), and complement component 2 (C2) in 183 controls and 730 patients with increasing severity of AMD from the Muenster aging and retina study (MARS). Severity scoring was based on the Rotterdam classification of fundus photographs. Results Compared with controls, patients with very early AMD showed a significantly increased minor allele frequency (MAF) only for CFH-rs1061170. With increasing severity of AMD, SNPs in CFH-rs1061170, as well as ARMS2-rs10490924, became consistently more common (Po0.001). Likewise, HtrA1-rs11200638 was less clearly associated with AMD severity, whereas C2-rs9332739 and CFB-rs641153 showed no relation. Multifactorial models confirmed CFH and ARMS2 as major determinants of AMD severity, whereas addition of HtrA1, C2 and CFB did not improve model prediction. In the models, age did not contribute to very early but to all more severe AMD stages, whereas smoking history had a significant impact only for late AMD.
Introduction
Age-related macular degeneration (AMD) is a chronic disease of the retina and the leading cause of visual impairment and legal blindness among older people in industrialised countries. 1, 2 The early stages of AMD are characterised by intermediate or large soft drusen and hyper-or hypopigmentation of the retinal pigment epithelium with usually only minor or no clinical symptoms. 3, 4 Extension, type, and bilateral concurrence of morphologic alterations of the retina are closely related to the risk of progression to advanced AMD, geographic atrophy (GA), and choroidal neovascularisation (CNV), 5 which commonly cause vision impairment and blindness.
Numerous studies have indicated that AMD is a complex, multifactorial disease with a prominent genetic component despite a disease onset late in life. 4, 6 Common single nucleotide polymorphisms (SNPs) in the complement factor H (CFH) gene on chromosome 1, [7] [8] [9] [10] and in two loci on chromosome 10q26, that is, ARMS2 (formerly labelled as LOC387715) [11] [12] [13] [14] [15] and the HtrA serinepeptidase 1 (HtrA1) gene [16] [17] [18] [19] showed strong associations with the risk of advanced AMD. These results have been extensively replicated in studies conducted in various populations and settings (for an overview, see Jakobsdottir et al 20 )
. Additional studies investigated the complement pathways in more detail. Their findings indicated that genes coding for other elements of the complement system, such as component 2 (C2) and complement factor B (CFB) on chromosome 6p, might be involved in a protective manner. [20] [21] [22] [23] As emphasised by Jakobsdottir et al, 20 many genetic association studies have compared cases of advanced AMD with eye-healthy controls to enhance phenotypic contrast. Much less is known about the role of genetic variants for AMD onset and the course of the early forms of AMD. Some studies have included groups of individuals with conditions labelled as early AMD 23, 24 or low-risk AMD, 12 whereas others investigated in more detail how genetic variants relate to specific morphologic features of early AMD. 12, [24] [25] [26] [27] [28] [29] These studies reported that the allelic risk variants of the CFH gene were more frequent among early AMD cases compared with controls but that the risk was much stronger among patients with more advanced disease. 12, [24] [25] [26] 29 Similarly, Rivera et al 12 showed for the ARMS2-rs10490924 variant, a slightly higher frequency in patients with early AMD, whereas substantially increased frequencies were observed in patients with late AMD. Recently, it was hypothesised that genetic variations in the CFH locus contributed to global and diffuse retinal disease, including early maculopathy and extramacular parts of the retina, while the ARMS2 variant and HtrA1-rs11200638 appeared mainly related to the angiogenic pathway and specifically to neovascularisation. 16, 17, 28, 30, 31 Moreover, some new studies suggested that SNPs in the C2-CFB locus may also effect the development of early signs of AMD, such as drusen formation due to a modified activity of the complement cascade. 20, 21, 23 We present here analyses on a sample of 183 controls and 730 individuals who were classified into four groups according to rising severity of AMD, and we investigated how the occurrence of allelic variants in the CFH, ARMS2, HtrA1, C2, and CFB genes differed across these stages of severity.
Materials and methods

Study population
The Muenster aging and retina study (MARS) is a longitudinal study designed to identify medical, environmental, and genetic factors with implications for the progression of AMD. From June 2001 to October 2003, a cohort of 1060 individuals from the city of Muenster and the surrounding counties was assembled. [32] [33] [34] All participants were of Caucasian origin. A cross-sectional analysis of this baseline examination is the basis of the present report.
Study subjects were eligible as AMD patients for inclusion to MARS when they had morphologic evidence of early AMD in at least one eye and if age at diagnosis was between 60 and 80 years. Individuals with severe cataract, a diagnosis of narrow-angle glaucoma or with severe myopia were not eligible. Control subjects were recruited on an opportunistic basis from volunteers, spouses, and unrelated companions of the AMD cases if they agreed to a mydriatic ophthalmic examination, which showed no signs of AMD after grading their fundus photographs in a masked way.
The recruitment and research protocols were reviewed and approved by the Institutional Review Board of the University of Muenster, and written informed consent was obtained from all study participants.
Examination procedures and fundus photography
Examination procedures and fundus photography have been previously described in detail. 32 All digital images were evaluated on a 22-inch computer screen by specially trained technicians. The presence and severity of retinal lesions were graded according to the protocol of the International age-related maculopathy (ARM) Epidemiological Study Group. 3 We graded each eye of a study individual independently, and we included individuals in this report only when the grading in both eyes was possible. We employed the fundus grading system of the International ARM Epidemiological Study Group 3 for AMD. In accordance with the Rotterdam study classification, 2 the range of fundus signs was stratified into a five severity stages: stage 0, no sign of ARM or hard drusen (o63 mm) only; stage 1, soft distinct drusen (X63 mm) only, or pigment epithelium changes only, no soft drusen (X63 mm); stage 2, soft indistinct drusen (X125 mm) or reticular drusen only, or soft distinct drusen (X63 mm) with pigment epithelium changes; stage 3, soft indistinct drusen (X125 mm) or reticular drusen with pigment epithelium changes; and stage 4, atrophic or neovascular AMD. Subjects were classified according to the stage in the eye with the worse finding.
DNA extraction, SNP selection, and genotyping
We extracted DNA from peripheral blood by standard methods. Variants within the CFH (rs1061170, rs2274700, and rs3766404), ARMS2 (rs10490924 and rs10490923), Eye HtrA1 (rs11200638), CFB (rs12614, rs547154, rs641153, rs1048709, and rs2072633), and C2 (rs4151659, rs4151667, and rs9332739) genes were genotyped. For genotyping, we used 2 ng genomic DNA and Taqman SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) following the manufacturers' instructions.
The polymerase chain reaction (PCR) was specifically employed to characterise the three SNPs rs11200638 (HtrA1), rs641153 (CFB), and rs12614 (CFB). We used the oligonucleotide primers 5 0 CACCCTCGCCAGTTACGA 35 We investigated the frequencies of 14 SNPs in five genes. We excluded three SNPs (rs3766404, rs10490923, and rs547154) from further analyses as their genotyping call rates were o90%. For the sake of conciseness and clarity, we further present results only for one SNP from each gene. Therefore, CFH-rs2274700, C2-rs4151667, and C2-rs4151659, as well as CFB-rs12614, CFB-rs1048709, and CFB-rs2072633 were excluded because the association for each of these variants with AMD severity stages was less strong than for the SNPs retained in this report.
Statistical analyses
Of the 1060 participants of the MARS baseline examination, digital fundus images were not obtained for the following reasons: refusal (two patients), technical problems of the retina camera (5 right and 15 left eyes), severe opacities of the lens or cornea in one eye (six right and five left eyes), and insufficient dilatation (two right and five left eyes). Because of other adverse eye conditions (eg, gliosis, diabetic retinopathy, and so on), the AMD grade could not be assessed in 44 right and 40 left eyes. Furthermore, no DNA was provided by 51 participants and genotyping was not successful in another 11 subjects. Thus, genotyping and gradable digital fundus photographs in both eyes were available for 913 subjects (86% of all study participants).
We defined genotypes as categorical variables with three levels. We used logistic regression models to assess the association of single SNPs with AMD severity level under the assumption of an additive model on a log scale as also used by others. 12, 14, 31, 36 In a first step, odds ratios (ORs) were computed for one copy of the risk allele separately for each SNP. The statistical power of each severity group was calculated for every SNP using the freeware online tool 'Genetic Power Calculator'. 37 We assessed the contributions of variants in different genes at each severity stage by fitting logistic regression models that included the CFH variant (rs1061170), and, in consecutive order, additionally ARMS2-rs10490924, HtrA1-rs11200638, C2-rs9332739, and CFB-rs641153. Finally, age, gender, and smoking status were included to identify the independent impact of these non-genetic variables on AMD severity. Model performance was evaluated using the area under the ROC curve (or c-statistics) to assess the discriminatory power of the model. 38 To account for the number of statistical comparisons performed for each SNP, we adjusted the statistical significance level to the number of AMD stages (a/n, ie, 0.05/4 ¼ 0.0125), and report exclusively 99% confidence intervals. Likewise, statistical significance of a result was accepted if the error level was less than 1%. All analyses were performed using STATA 9.0 and SAS 9.1.
Results
Baseline description of the study sample
The control group in our study sample consisted of 183 individuals who had no signs of AMD. The cases with advancing severity of AMD among the MARS participants were similar to those with different levels of maculopathy, although there were 280 individuals with late AMD in at least one eye (Table 1) . Patients with more severe AMD were older and they had more often smoked during their lifetime. The proportion of women in each stage ranged from 54 and 70%.
AMD severity stages and genetic variants Figure 1 shows the minor allele frequencies (MAFs) of the five SNPs in groups of AMD severity. All variants were in HWE in the controls. Although SNPs in the CFH (MAF ¼ 0.336), ARMS2 (0.240), and HtrA1 (0.351) genes were common among controls, SNPs in the C2 (0.024) und CFB (0.040) genes were quite rare ( Figure 1 and Supplementary Table) . The MAF rose consistently with AMD stage for CFH, ARMS2, and HtrA1 (test for trend, Po0.001) but no clear relation emerged for C2 and CFB (Supplementary Table) . These associations were generally confirmed when fitting separate logistic regression models (Table 2) . We found that in stage 1, CFH-rs1061170 was the only SNP with a significantly elevated OR, and that the magnitude of the ORs increased in a graded manner up to the higher severity levels. By comparison, the OR for ARMS2-rs10490924 and for HtrA1-rs11200638 was not significantly raised in stage '1', but from stage '2' upwards, a graded risk increase was observed. The impact of HtrA1-rs11200638 seemed less pronounced than for ARMS2-rs10490924 (maximum OR: 1.9 vs 2.6).
To further clarify the association between ARMS2 and HtrA1, we did a fine mapping of this region, that revealed only a low linkage disequilibrium between ARMS2-rs10490924 and HtrA1-rs11200638 (D 0 ¼ 0.44).
Moreover, the OR for C2-rs9332739 oscillated around unity across AMD severity levels and showed no statistical significance. Although a consistent tendency towards a protective effect was found for CFB-rs641153, the individual ORs (ranging from 0.3 to 0.6) did not reach statistical significance.
Multifactorial models
The logistic regression models that included only one SNP generally contributed rather moderately to the . This was mostly due to significant impacts of age in these models, whereas the effect of smoking history was of only significance in stage 4 patients. Gender had no significant influence at any AMD severity level.
Discussion
In this cross-sectional analysis, we took a focused view on how genotypes relate to the different stages of AMD severity. We found that only the SNP CFH-rs1061170 was related to the earliest AMD stages. These results are in agreement with earlier reports, [24] [25] [26] 39 and indicate that the CFH gene seems to play a key role already in the onset of AMD. SNPs from both, the CFH and the ARMS2 gene, were more common among patients with more severe AMD. The increments with every severity stage were steady and strong; ORs for the presence of a single allele copy increased substantially in the late stages of AMD. We view the graded rise as evidence of the relative importance of the two SNPs in the progression of AMD.
HtrA1-rs11200638 showed significant effects, but of lower strength, and its contribution in the multifactorial models was insignificant. This result is not supporting an independent role of this variant as claimed by other reports. 31, 36 Fine mapping of the ARMS2/HtrA1 region revealed a low linkage disequilibrium between ARMS2-rs10490924 and HtrA1-rs11200638
supporting the hypothesis that ARMS-rs10490924 represents the major susceptibility polymorphism of this region and that HtrA1-rs11200638 is only indirectly associated with AMD. 14, 15 Our analysis of the C2-CFB-locus was inconclusive. The risk variants C2-rs9332739 and CFB-rs641153 were rare in the MARS study sample and appeared unrelated to AMD severity. Nevertheless, our results do not rule out the protective roleFespecially of CFBrs641153Fthat was claimed by others, [20] [21] [22] [23] because the statistical power of our study was too low to provide conclusive confirmation or refutation of these results. The inclusion of C2/CFB in multifactorial analyses did also not significantly improve the prediction contrary to the finding of Jakobsdottir et al. 20 We note, however, that these authors used a different SNP in the CFB gene (rs4151667) while confirming our result of no association of C2-rs9332739 with AMD.
Our analytic approach compares the proportions of individuals who carry at least one copy of the respective SNP in each severity level. We note that this proportion depends, aside from sampling variation, also on the relative impact of other causative factors. We assumed that, under a model of component causes, the proportion of carriers of the risk allele in each severity stage is an indicator of the relative importance of this SNP within a sufficient cause. 40 Presently, it is not clearly understood how genetic factors influence the onset and advancement of AMD, 6 and it has to be noted that the variants in the five genes studied here exert various functions and are involved in different biological processes and/or pathways. CFH, for example, is the major inhibitor of the alternative complement cascade, 41, 42 and has previously been associated with drusen formation. 25, 26 The function of the ARMS2 gene was poorly understood 6, 12 until recently when Fritsche et al 14 could show that the expression of ARMS2 is present in mitochondria of cells among others of the human retina. In line with recent findings of Kanda et al, 15 they propose that ARMS2 has a key role in AMD, possibly through mitochondrial-related pathways. 14 Presently, the role of HtrA1, located very close to ARMS2 on 10q26 and coding for a well-characterised heat-shock protease, is less clear. Evidence for a significant role of HtrA1 in AMD was proposed by Yang et al 17 who showed a positive HtrA1 staining in drusen and found an enhanced HtrA1 expression in the RPE of AMD patients carrying the rs11200638 variant. C2 and CFB are paralogous genes on chromosome 6p21 that aid the initiation of the complement cascade. The key role of C2 and CFB in AMD pathobiology seems to be the regulation of the complement activation, and hence the influence in inflammatory processes. 20, 21, 23 Finally, the contribution of non-genetic factors in our study was modest and confined to age and, less markedly, to smoking history. We noted a significant influence only in the later stages of AMD.
There are limitations to our study. First, MARS is not a population-based sampling, and used as a clinical convenience sampling. However, all tested SNPs were in HWE, especially in our control group, indicating that our reference group does not appear to be grossly biased by selection. We compared the MAF and the proportions of genotypes in our control group with reports from the literature representing European populations of Eye Caucasian descent. We found that the MAF for CFH-rs1061170, ARMS2-rs1049024, and C2-rs9332739 were in very good agreement with reports from population-based samples. 12, 20, 36, 43 Hence, the reported ORs can be assumed to be unbiased. On the other hand, we found significantly higher MAF for HtrA1-rs11200638 and clearly lower MAF for CFB-rs641153 compared with other populations 21, 23, 31, 36 supposedly due to the different genotyping methods used. We employed the resequencing method, which is regarded as the goldstandard of genotyping methods. Therefore, we suppose that these MAF in our control group are valid and that it is unlikely that they are based on a sampling error.
Second, controls in our study may still develop AMD later in life. Although this is true, we do not conceive that this invalidates our analytic approach; stages of severity in an age-related disease imply, by definition, that the mean years of age differ by stage. We suggest that causal contributions may be inferred when the exposure is a biologically invariable factor (eg, genetic makeup), and selective survival or participation bias can be plausibly excluded. We are not aware that the genetic traits evaluated here confer any survival disadvantage, nor can we conceive of any selective participation conditional on the genotypes.
Third, examination methods, such as angiography, are better for the accurate diagnosis of late stage AMD, especially the differential diagnosis of CNV, than fundus photos. However, these more laborious examination methods are difficult to obtain in larger scale epidemiological studies, and therefore, most study results concerning the association of polymorphisms and AMD are, like MARS, restricted to fundus photos. Fourth, statistical power analysis revealed a 90% power to detect an association at a ¼ 0.05 through the transmission disequilibrium test analysis for the risk variants of CFH-rs1061170, ARMS2-rs10490924, and HtrA1-rs11200638 at every severity stage. On the other hand, the statistical power was insufficient for the minor alleles in the C2 and CFB genes to detect significant associations, as also denoted above. We do not believe, however, that these low MAF are biased by sampling errors but that they correctly reflect the situation in this population from the Northwest of Germany.
Conclusion
Our findings support the notion that the CFH gene is involved in the onset of AMD, although both, the CFH and ARMS2 genes, and more weakly the HtrA1 gene, account for the advancement of AMD. The results of SNPs in the C2 and CFB genes were inconclusive. Genetic factors dominated in their impact on AMD severity over non-genetic factors, that is, age and smoking history. Clearly, prospective studies are needed to further clarify the impact of genetic factors on AMD progression. We hope that the prospective analyses of the MARS cohort, which are presently under way, will be able to contribute to this clarification.
